When does DBV.PA report earnings and why does it matter?

DBV.PA earnings are scheduled for **23 Mar 2026**. The report matters because updates on Viaskin trials, cash runway and partnership milestones can change short-term valuation and trigger intraday volatility on EURONEXT.

What is Meyka AI's price forecast for DBV.PA stock?

Meyka AI's forecast model projects a one-year value of **€4.16**, implying about **22.35%** upside from the current **€3.40**. Forecasts are model-based projections and not guarantees.

What are the main risks for DBV.PA stock after earnings?

Key risks include negative EPS of **-0.90**, binary clinical trial outcomes, high R&D spending at **79.82%** of revenue, and potential dilution if additional financing is needed.

How does sector performance affect DBV.PA stock?

Biotechnology peers trade at higher multiples (sector P/E ~**29.62**). Positive clinical news can narrow that valuation gap, while setbacks typically widen it and increase downside pressure.

EU Stocks

Earnings due 23 Mar: DBV.PA DBV Technologies EURONEXT, Viaskin read-through ahead

ByHuzaifa Zahoor March 20, 2026

DBV.PA stock heads into an upcoming earnings release on 23 Mar 2026, trading intraday at €3.40 on EURONEXT as of 20 Mar 2026. Investors will watch for progress on the Viaskin clinical programme and any cash runway updates. Volume today is 614,887 shares versus a 50-day average of 1,447,445 shares, signalling lighter intraday liquidity but focused interest ahead of the report. We use fundamentals, technicals and our earnings checklist to frame likely market reactions.